Find A Clinical Trial
Disease Type: Lung
A Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR Exon 20 Insertion Mutations
Safety, Pharmacokinetics, and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase 1A/1B Study
A Phase 2 Open-Label, Multicenter Randomized Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-Stage (II-IIIA) NSCLC
A Phase 2 Trial of Neoadjuvant and Adjuvant Capmatinib in Participants with Stages IB-IIIA, N2, and Selected IIIB (T3N2 or T4N2) NSCLC with MET Exon 14 Skipping Mutation or High MET Amplification
A Phase 1/2 Open-Label Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutated, Metastatic NSCLC Who Have Progressed After Treatment with Osimertinib
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and other Solid Tumors
A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiation Followed by Ociperlimab Plus Tislelizumab or Tislelizumab Plus CCRT Followed by Tislelizumab Versus CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced, Unresectable NSCLC
A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Pembrolizumab or Budigalimab
A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
A Phase 1/1b Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF-006 in Patients with Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients with KRAS-Mutated Non-Small Cell Lung Cancer.